Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is ...
The research field of 'cellular IRESes' lay dormant for decades, as there was no uniform standard of reliable methods for the clear characterization of these starting points for the ribosome-mediated ...
Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated ...
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI ...
A new study published in The Journal of Immunology found that a high-salt diet (HSD) induces depression-like symptoms in mice by driving the production of a protein called IL-17A. This protein has ...
"By continuously advancing our AI platform with a deep understanding of atomic-level protein interactions, we aim to transform therapeutic drug discovery, improving both efficiency and success rates." ...
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Protein clustering mechanism on the cell membrane presents a new therapeutic target for cystic fibrosis. A new study from The Hospital for Sick Children (SickKids) reveals the process underlying ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback